Article underlines Actinium Pharma's progress in acute myeloid leukemia

10 August 2016

USA-based Actinium Pharmaceuticals (NYSE MKT: ATNM) is edging closer to an effective treatment for acute myeloid leukemia (AML), according to an Online Media Group article.

This form of leukemia, which comes in eight different sub-types, has no standard of care and the prognosis for survival time is often measured in months, if not weeks.

The article by senior staff writer Elliot Schleicher highlights Actinium, one of only a handful of companies using alpha particle linked antibodies to treat cancer, for the progress it is making in advancing its products down the clinical path to address this great unmet medical need.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK